While the importance of RGS-GAIP-interacting protein (GIPC) in the biology of malignant cells is well known, the molecular mechanism of GIPC in the inhibition of tumor progression has not been identified. This study focused on elucidating the molecular role of GIPC in breast cancer progression. By using a human breast tumor specimen, an in vivo mouse model, and breast cancer cell lines, we showed for the first time that GIPC is involved in breast cancer progression through regulation of breast cancer cell proliferation, survival, and invasion. Furthermore, we found that the Akt/Mdm2/p53 axis, insulin-like growth factor-1 receptor (IGF-1R), matrix metalloproteinase-9 (MMP-9), and Cdc42 were downstream of GIPC signaling in breast cancer cells. Moreover, we showed that wild-type p53 reduced GIPC-induced breast cancer cell survival, whereas mutant p53 inhibited GIPC-induced cell invasion. Finally, we demonstrated that a myristylated GIPC peptide (CR1023, Myristoyl-PSQSSSEA) capable of blocking the PDZ domain of GIPC successfully inhibited MDA-MB-231 cell proliferation, survival, and further in vivo tumor growth. Taken together, these findings demonstrate the importance of GIPC in breast tumor progression, which has a potentially significant impact on the development of therapies against many common cancers expressing GIPC, including breast and renal cancer.
Migration and invasion assay:
Cell migration was performed as described previously (7) . FBS (10%) was added as the chemoattractant in the lower well of the chambers.
The invasion assay was performed similarly except that the transwell chambers were coated with 4 mg/mL Matrigel (BD Biosciences, San Jose, CA), and the incubation time was 16 hours.
Flow cytometry analysis: siRNA-transfected cells were collected and apoptosis was assessed using the Annexin V-FITC/PI Apoptosis Detection Kit (BioVision, Inc., Mountain View, CA) according to the manufacturer's instructions. Apoptotic cells and necrotic/late-apoptotic cells were measured using the FACSCalibur analysis system (Becton Dickinson, CA).
Rho family GTPase activities assay:
Cells were seeded at roughly 1 x 10 6 cells per 60 mm in a tissue culture dish. After a 24-hour incubation in serum-free medium, RhoA, Cdc42, and Rac1 activities were assessed using the G-LISA RhoA, Cdc-42, and Rac1
Activation Assay Biochem Kits (Cytoskeleton, Inc., Denver, CO) according to the manufacturer's protocol.
Myristlated peptide design:
We have designed an octapeptide (Myristoyl-PSQSSSEA, designated as CR1023) possessing the SEA-binding motif, a control peptide (Myristoyl-SESPSASQ, designated as CR2055), and a fluorescein isothiocyanate (FITC)-conjugated GIPC peptide (Myristoyl-K(FITC)PSQSSSEA, designated as CR1171), as described previously (8). 
Statistical analysis:
Statistical analyses were performed with the statistical SPSS 11.0 software (SPSS, Inc.). The independent-sample t test was used to test the probability of significant differences between groups. 
Results
The role of GIPC in tumor progression. To assess the role of GIPC in breast cancer progression, we purchased human breast tumor specimens from US Biomax and screened tissue microarrays of normal and tumor tissues using immunohistochemistry.
As shown by arrows in Figure 1A , GIPC expression was observed mainly on the luminal portion of the infiltrating ductal carcinoma (IDC) and was confined to epithelial cells.
Importantly, there was significantly higher cytoplasmic GIPC expression in tumor samples compared to normal breast tissue and in undifferentiated IDC compared to moderately differentiated IDC ( Figure 1A and Supplemental Table) . These results suggest that GIPC expression correlates with disease progression.
Furthermore, we investigated whether GIPC was required for breast cancer growth in an in vivo tumor xenograft model. Stable MDA-MB-231 transfectants were prepared with shRNA expressing the GFP vector alone or shRNA silencing GIPC expression.
Protein lysates from these cells were prepared and analyzed by Western blotting to verify the knockdown of GIPC ( Figure 1B ). These cell lines were then injected subcutaneously into female nude mice to evaluate the role of GIPC in breast tumor growth. Tumor volumes were recorded weekly. Mice injected with the GIPC-depleted transfectants developed smaller tumors, as determined by a decrease in size compared with mice injected with control GFP-labeled MDA-MB-231 cells ( Figure 1B ). These results provide evidence that GIPC is involved in breast cancer progression. Figure 2A , GIPC is strongly expressed in both cell lines.
Expression of GIPC in
GIPC contributes to breast cancer cell proliferation, survival, and invasion. We then examined the influence of GIPC on the proliferation of these breast cancer cell lines. Cell proliferation was examined by MTS assay after the cells were transfected with GIPC-targeting siRNA (GIPC siRNA) oligonucleotides. In both cell lines, cell viability and proliferation were decreased in cells treated with GIPC siRNA compared with those treated with control siRNA ( Figure 2B ).
The decrease in proliferation in the absence of GIPC suggests that GIPC may also The role of GIPC in the migration and invasion of MDA-MB-231 was investigated.
As shown in Figures 2B and 2D Akt-Mdm2-p53 signaling is involved in the GIPC signaling pathway. The phosphatidylinositol 3-kinase/Akt (PI3K/Akt) pathway is a common signaling pathway that mediates cell proliferation, survival, and migration. It is also well-known that serine 166 and serine 186 of Mdm2 serve as targets for direct Akt phosphorylation (9, 10).
Also, phosphorylation of Mdm2 by Akt enables Mdm2 translocation from the cytoplasm into the nucleus and the subsequent inactivation of nuclear p53 (9) . Because Mdm2 is a major physiological regulator of p53 function, we tested whether GIPC acts through Aktmediated Mdm2 phosphorylation to inhibit the apoptotic effects of p53 activity and subsequently increase cell survival. As shown in Figure 3A , knockdown of GIPC significantly reduced Akt phosphorylation, downregulated phospho-Mdm2, and increased p53 expression in both MDA-MB-231 and MCF-7 cells, suggesting that GIPCmediated breast cancer cell proliferation, survival, and migration/invasion may be due to the involvement of the Akt/Mdm2/p53 pathway. 
IGF-1R is downstream of GIPC signaling in breast cancer cells. IGF-1R plays
important roles in cell signaling, proliferation, differentiation, and apoptosis (11) . It was previously reported that GIPC is associated with IGF-1R and is important to its stability (4, 8) . We investigated whether GIPC regulates IGF-1R protein expression in both MDA-MB-231 and MCF-7. As shown by Western blot, IGF-IRβ levels significantly decreased in both cell lines after treatment with GIPC siRNA ( Figure 3B ). Furthermore, we analyzed the effect of GIPC on IGF-IRβ phosphorylation on MDA-MB-231 cell and found that knockdown of GIPC also reduced the phosphorylation of IGF-IRβ ( Figure   3B ).
Involvement of MMP-9 and Cdc42 in GIPC-mediated breast cancer cell invasion.
Matrix metalloproteinase-9 (MMP-9) preferentially degrades denatured collagens and native collagen type IV, a major component of extracellular matrix and basement membranes whose disruption is central to tumor invasion and metastasis (12, 13) . Our analysis of conditioned medium with gelatin zymography revealed that the release of MMP-9 was significantly reduced in MDA-MB-231 cells deficient in GIPC expression ( Figure 3C ).
Small Rho family GTPases (RhoA, Rac1, and Cdc42) are associated with the morphological transformation of tumor cells and have been linked to tumor cell migration and invasion (14) . We thus investigated the effects of GIPC on the activities of RhoA, Rac1, and Cdc42 in MDA-MB-231 by ELISA. We found that knockdown of GIPC reduced Cdc42 activity (p<0.01) ( Figure 3D ), whereas the activities of Rac-1 and RhoA compared with cells transfected with GIPC siRNA alone, which suggests that wild-type p53 in MCF-7 is involved in cell survival through GIPC signaling. We also checked cell survival in MDA-MB-231 cells solely transfected with p53 siRNA and found that the knockdown of mutant p53 has no effect on their cell survival (data not shown),
suggesting that this mutant p53 has lost its tumor suppressive ability. Similar to apoptosis, MDA-MB-231 invasion was increased in cells that were deficient in both GIPC and p53 ( Figure 4B ). This suggests that mutant p53 in MDA-MB-231 (TP53) is involved in the GIPC-mediated cell invasion. To determine the localization of the peptides in wild-type MDA-MB-231 cells, the GIPC CR1023 peptide was conjugated to 5-carboxyfluorescein. Fluorescence images were collected; Figure 5D shows the internalizaton of CR1023 (green) in relation to 4',6- status. The MDA-MB-231 cell has a mutant p53 (TP53), whereas MCF-7 has a wildtype p53. Therefore, this result suggests that wild-type p53 mediates breast cancer cell apoptosis through GIPC, while mutant p53 loses its tumor-suppressive role. A previous study (20) found that wild-type p53 is crucial in regulating cell growth and apoptosis.
Blockage of the PI3K pathway caused G 1 -S-phase arrest, decreased cell growth, and increased chemo-and radio-therapeutic sensitivity in MCF-7 cells that express wild-type p53. However, it did not increase the sensitivity to adriamycin in MDA-MB-453 breast cancer cells that express mutant p53. This result supports our findings. 
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